Tumor vascular leakiness and blood volume estimates in oligodendrogliomas using perfusion CT: An analysis of perfusion parameters helping further characterize genetic subtypes as well as differentiate from astroglial tumors

Journal of Neuro-Oncology

Volumn 102, Issue 2, 2011, Pages 287-293

  Narang, Jayant ^a   Jain, Rajan ^a   Scarpace, Lisa ^a   Saksena, Sona ^a   Schultz, Lonni R ^a   Rock, Jack P ^a   Rosenblum, Mark ^a   Patel, Suresh C ^a   Mikkelsen, Tom ^a  

^a HENRY FORD HEALTH SYSTEM   (United States)

Author keywords

Astroglial tumors; Oligodendroglioma; Perfusion CT; Permeability; Vascular leakiness

Indexed keywords

ADULT; AGED; ARTICLE; ASTROGLIAL TUMOR; BLOOD VESSEL PERMEABILITY; BRAIN BLOOD VOLUME; CANCER GRADING; CENTRAL NERVOUS SYSTEM TUMOR; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; FEMALE; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OLIGODENDROGLIOMA; RETROSPECTIVE STUDY; TUMOR VASCULARIZATION;

ADULT; AGED; ASTROCYTOMA; BLOOD VOLUME; BRAIN NEOPLASMS; CEREBROVASCULAR CIRCULATION; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; OLIGODENDROGLIOMA; PERFUSION IMAGING; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; YOUNG ADULT;

EID: 79953685458     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-010-0317-3     Document Type: Article

References (39)

1. Behin A, Hoang-Xian K, Carpentier AF, Delattre JY (2003) Primary brain tumors in adults. Lancet 361:323-331. doi: 10.1016/s0140-6736(03)12328-8
2. Fortin D, Cairncross GJ, Hammond RR (1999) Oligodendroglioma: an appraisal of recent data pertaining to diagnosis and treatment. Neurosurgery 45:1279-1291
3. Engelhard HH, Stelea A, Cochran EJ (2002) Oligodendroglioma: pathology and molecular biology. Surg Neurol 58:111-117 (Pubitemid 35365906)
4. Engelhard HH, Stelea A, Mundt A (2003) Oligodendroglioma and anaplastic oligodendroglioma: clinical features, treatment, and prognosis. Surg Neurol 60:443-456 (Pubitemid 37323986)
5. Cairncross JG, Macdonald DR (1988) Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol 23:360-364. doi:10.1002/ana.410230408 (Pubitemid 18098242)
6. Coons SW, Johnson PC, Pearl DK (1997) The prognostic significance of Ki-67 labeling indices for oligodendrogliomas. Neurosurgery 41:878-884
7. Van den Bent MJ, Looijenga LH, Langenberg K, Dinjens W, Graveland W, Uytdewilligen L, Sillevis Smitt PA, Jenkins RB, Kros JM (2003) Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features. Cancer 97:1276-1284. doi:10.1002/cncr.11187 (Pubitemid 36237315)
8. Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, Silver JS, Stark PC, Macdonald DR, Ino Y, Ramsay DA, Louis DN (1998) Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90:1473-1479 (Pubitemid 28482012)
9. Shaw EG, Scheithauer BW, O'Fallon JR, Tazelaar HD, Davis DH (1992) Oligodendrogliomas: the Mayo Clinic experience. J Neurosurg 76:428-434. doi:10.3171/jns.1992.76.3.0428
10. Aronen HJ, Gazit IE, Louis DN, Buchbinder BR, Pardo FS, Weisskoff RM, Harsh GR, Cosgrove GR, Halpern EF, Hochberg FH et al (1994) Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. Radiology 191:41-51
11. Lev MH, Ozsunar Y, Henson JW, Rasheed AA, Barest GD, Harsh GRt, Fitzek MM, Chiocca EA, Rabinov JD, Csavoy AN, Rosen BR, Hochberg FH, Schaefer PW, Gonzalez RG (2004) Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas. AJNR Am J Neuroradiol 25:214-221 (Pubitemid 38235298)
12. Lev MH, Rosen BR (1999) Clinical applications of intracranial perfusion MR imaging. Neuroimaging Clin N Am 9:309-331 (Pubitemid 29263861)
13. Law M, Yang S, Wang H, Babb JS, Johnson G, Cha S, Knopp EA, Zagzag D (2003) Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol 24:1989-1998 (Pubitemid 37444849)
14. Hakyemez B, Erdogan C, Ercan I, Ergin N, Uysal S, Atahan S (2005) High-grade and low-grade gliomas: differentiation by using perfusion MR imaging. Clin Radiol 60:493-502. doi: 10.1016/j.crad.2004.09.009 (Pubitemid 40353027)
15. Rijpkema M, Schuuring J, van der Meulen Y, van der Graaf M, Bernsen H, Boerman R, van der Kogel A, Heerschap A (2003) Characterization of oligodendrogliomas using short echo time 1H MR spectroscopic imaging. NMR Biomed 16:12-18. doi: 10.1002/nbm.807 (Pubitemid 36284831)
16. Ellika SK, Jain R, Patel SC, Scarpace L, Schultz LR, Rock JP, Mikkelsen T (2007) Role of perfusion CT in glioma grading and comparison with conventional MR imaging features. AJNR Am J Neuroradiol 28:1981-1987. doi:10.3174/ajnr.A0688 (Pubitemid 350174746)
17. Cha S, Tihan T, Crawford F, Fischbein NJ, Chang S, Bollen A, Nelson SJ, Prados M, Berger MS, Dillon WP (2005) Differentiation of low grade oligodendrogliomas from low grade astrocytomas using quantitative blood volume measurements derived from dynamic susceptibility contrast enhanced MR imaging. AJNR Am J Neuroradiol 26:266-273 (Pubitemid 43073303)
18. Jain R, Ellika SK, Scarpace L, Schultz LR, Rock JP, Gutierrez J, Patel SC, Ewing J, Mikkelsen T (2008) Quantitative estimation of permeability surface-area product in astroglial brain tumors using perfusion CT and correlation with histopathologic grade. AJNR Am J Neuroradiol 29:694-700. doi:10.3174/ajnr.A0899 (Pubitemid 351571548)
19. Jain R, Scarpace L, Ellika S, Schultz LR, Rock JP, Rosenblum ML, Patel SC, Lee TY, Mikkelsen T (2007) First-pass perfusion computed tomography: initial experience in differentiating recurrent brain tumors from radiation effects and radiation necrosis. Neurosurgery 61:778-786. doi:10.1227/01.neu.0000298906. 48388.26 (Pubitemid 350073285)
20. Pech IV, Peterson K, Cairncross JG (1998) Chemotherapy for brain tumors. Oncology (Williston Park) 12:537-543 (Pubitemid 128617847)
21. Friedman HS, Lovell S, Rasheed K, Friedman AH (1998) Treatment of adults with progressive oligodendroglioma with carboplatin (CBDCA): preliminary results. Writing Committee for the Brain Tumor Center at Duke. Med Pediatr Oncol 31:16-18 (Pubitemid 28243695)
22. Soffietti R, Ruda R, Bradac GB, Schiffer D (1998) PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas. Neurosurgery 43:1066-1073 (Pubitemid 28481106)
23. Chinot O (2001) Chemotherapy for the treatment of oligodendroglial tumors. Semin Oncol 28:13-18
24. Christov C, Adle-Biassette H, Le Guerinel C, Natchev S, Gherardi RK (1998) Immunohistochemical detection of vascular endothelial growth factor (VEGF) in the vasculature of oligodendrogliomas. Neuropathol Appl Neurobiol 24:29-35 (Pubitemid 28105411)
25. Pietsch T, Valter MM, Wolf HK, von Deimling A, Huang HJ, Cavenee WK, Wiestler OD (1997) Expression and distribution of vascular endothelial growth factor protein in human brain tumors. Acta Neuropathol 93:109-117 (Pubitemid 27060902)
26. Maia AC Jr, Malheiros SM, da Rocha AJ, da Silva CJ, Gabbai AA, Ferraz FA, Stavale JN (2005) MR cerebral blood volume maps correlated with vascular endothelial growth factor expression and tumor grade in nonenhancing gliomas. AJNR Am J Neuroradiol 26:777-783 (Pubitemid 43079767)
27. Netto GC, Bleil CB, Hilbig A, Coutinho LM (2008) Immunohistochemical evaluation of the microvascular density through the expression of TGF-b (CD 105/endoglin) and CD 34 receptors and expression of the vascular endothelial growth factor (VEGF) in oligodendrogliomas. Neuropathology 28:17-23. doi:10.1111/j.1440-1789.2007.00825.x
28. Law M, Yang S, Babb JS, Knopp EA, Golfinos JG, Zagzag D, Johnson G (2004) Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade. AJNR Am J Neuroradiol 25:746-755 (Pubitemid 38657655)
29. Jain R, Gutierrez J, Narang J, Rock J P, Scarpace L, Schultz LR, Lemke N, Patel SC, Mikkelsen T (in press) In vivo correlation of tumor blood volume and permeability with histological and molecular angiogenic markers in gliomas. Unpublished data
30. Xu M, See SJ, Ng WH, Arul E, Back MF, Yeo TT, Lim CC (2005) Comparison of magnetic resonance spectroscopy and perfusion-weighted imaging in presurgical grading of oligodendroglial tumors. Neurosurgery 56:919-926
31. Christov C, Gherardi RK (1999) Vascular endothelial growth factor (VEGF) likely contributes to oligodendroglioma angiogenesis. Acta Neuropathol 97(4):429-432
32. Varlet P, Guillamo JS, Nataf F, Koziak M, Beuvon F, Daumas-Duport C (2000) Vascular endothelial growth factor expression in oligodendrogliomas: a correlative study with Sainte-Anne malignancy grade, growth fraction and patient survival. Neuropathol Appl Neurobiol 26:379-389 (Pubitemid 30609434)
33. Spampinato MV, Smith JK, Kwock L, Ewend M, Grimme JD, Camacho DL, Castillo M (2007) Cerebral blood volume measurements and proton MR spectroscopy in grading of oligodendroglial tumors. AJR Am J Roentgenol 18:204-212. doi:10.2214/ajr.05.1177 (Pubitemid 46012510)
34. Whitmore RG, Krejza J, Huse J, Woo JH, Bloom S, Lopinto J, Wolf RL, Judy K, Rosenfeld MR, Biegel JA, Melhem ER, O'Rourke DM (2007) Prediction of oligodendroglial tumor subtype and grade using perfusion weighted magnetic resonance imaging. J Neurosurg 107:600-609. doi:10.3171/jns-07/09/0600 (Pubitemid 47451045)
35. Warnke PC, Berlis A, Ostertag C (1998) Physiological characterization of malignant oligodendrogliomas responding to PCV chemotherapy. J Neurosurg 88:399A
36. Jager HR, Waldman AD, Benton C, Fox N, Rees J (2005) Differential chemosensitivity of tumor components in a malignant oligodendroglioma: assessment with diffusion-weighted, perfusion-weighted, and serial volumetric MR imaging. AJNR Am J Neuroradiol 26:274-278 (Pubitemid 43073304)
37. Godfraind C, Rousseau E, Ruchoux MM, Scaravilli F, Vikkula M (2003) Tumour necrosis and microvascular proliferation are associated with 9p deletion and CDKN2A alterations in 1p/19q deleted oligodendrogliomas. Neuropathol Appl Neurobiol 29:462-464
38. Jenkinson MD, Smith TS, Joyce KA, Fildes D, Broome J, du Plessis DG, Haylock B, Husband DJ, Warnke PC, Walker C (2006) Cerebral blood volume, genotype and chemosensitivity in oligodendroglial tumors. Neuroradiology 48:703-713 (Pubitemid 44490047)
39. Kapoor GS, Gocke TA, Chawla S, Whitmore RG, Nabavizadeh A, Krejza J, Lopinto J, Plaum J, Maloney-Wilensky E, Poptani H, Melhem ER, Judy KD, O'Rourke DM (2009) Magnetic resonance perfusion-weighted imaging defines angiogenic subtypes of oligodendroglioma according to 1p19q and EGFR status. J Neurooncol 92:373-386. doi:10.1007/s11060-009-9880-x